Announcements
- UPCOMING MEETING: The Prescription Drug Affordability Board Meeting that was canceled on January 26, 2026 has been rescheduled to February 23, 2026 at 9:00 AM ET. Meeting information can be found here.
- Written Comment Request: In accordance with COMAR 14.01.05.06D(4), staff has posted its recommendation for a proposed UPL amount and methodology for Jardiance and Farxiga and is hereby requesting public written comment. Comments may be submitted in accordance with COMAR 14.01.01.05B(4) by close of business, Wednesday, March 4, 2026. More information can be found here.
What We Do
Cost Reviews
The Cost Review Study Process is the procedure by which the Board studies—that is, examines and analyzes—selected drugs to inform future policy recommendations and actions.
Public Meetings
Board Meetings and Stakeholder Council Meetings are both open to the public to provide transparency into the cost review process and the work of the PDAB.
Fee Assessments
PDAB assesses manufacturers, distributors, carriers and pharmacy benefits managers an annual assessment to fund the Prescription Drug Affordability Fund.
Contact us
Please reach out for any questions about fee assessments, public comments or general inquiries. For news and updates, join our mailing list.